


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:50:23Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406802" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406802</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>jimmthercanc</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="article-commentary" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Immunother Cancer</journal-id><journal-id journal-id-type="iso-abbrev">J Immunother Cancer</journal-id><journal-id journal-id-type="pmc-domain-id">2348</journal-id><journal-id journal-id-type="pmc-domain">jimmthercanc</journal-id><journal-id journal-id-type="publisher-id">jitc</journal-id><journal-title-group><journal-title>Journal for Immunotherapy of Cancer</journal-title></journal-title-group><issn pub-type="epub">2051-1426</issn><publisher><publisher-name>BMJ Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406802</article-id><article-id pub-id-type="pmcid-ver">PMC12406802.1</article-id><article-id pub-id-type="pmcaid">12406802</article-id><article-id pub-id-type="pmcaiid">12406802</article-id><article-id pub-id-type="pmid">40887107</article-id><article-id pub-id-type="doi">10.1136/jitc-2025-012728</article-id><article-id pub-id-type="publisher-id">jitc-2025-012728</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Commentary</subject></subj-group><subj-group subj-group-type="hwp-journal-coll"><subject>2520</subject><subject>1506</subject></subj-group></article-categories><title-group><article-title>HPV-positive HNSCC and Fc-silent PD-1 blockade: a clinical discrepancy that raises next immunological questions</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5616-902X</contrib-id><name name-style="western"><surname>Okuyama</surname><given-names initials="K">Kohei</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="cor1" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fujimoto</surname><given-names initials="J">Junya</given-names></name><xref rid="aff3" ref-type="aff">3</xref><xref rid="aff4" ref-type="aff">4</xref><xref rid="aff5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yanamoto</surname><given-names initials="S">Souichi</given-names></name><xref rid="aff6" ref-type="aff">6</xref></contrib><aff id="aff1"><label>1</label><institution content-type="department">Department of Cancer Biology</institution>, <institution>The University of Texas MD Anderson Cancer Center</institution>, <addr-line content-type="city">Houston</addr-line>, <addr-line content-type="state">Texas</addr-line>, <country>USA</country></aff><aff id="aff2"><label>2</label><institution content-type="department">Department of Oral and Maxillofacial Surgical Oncology</institution>, <institution>Institute of Science Tokyo Graduate School of Medical and Dental Sciences</institution>, <addr-line content-type="city">Bunkyo</addr-line>, <addr-line content-type="state">Tokyo</addr-line>, <country>Japan</country></aff><aff id="aff3"><label>3</label><institution content-type="department">Clinical Research Center</institution>, <institution>Hiroshima University Hospital</institution>, <addr-line content-type="city">Hiroshima</addr-line>, <country>Japan</country></aff><aff id="aff4"><label>4</label><institution content-type="department">Department of Medical Informatics</institution>, <institution>Hiroshima University Hospital</institution>, <addr-line content-type="city">Hiroshima</addr-line>, <country>Japan</country></aff><aff id="aff5"><label>5</label><institution content-type="department">Department of Translational Molecular Pathology</institution>, <institution>Graduate School of Biomedical and Health Sciences, Hiroshima University</institution>, <addr-line content-type="city">Hiroshima</addr-line>, <country>Japan</country></aff><aff id="aff6"><label>6</label><institution content-type="department">Department of Oral Oncology, Graduate School of Biomedical and Health Sciences</institution>, <institution>Hiroshima University</institution>, <addr-line content-type="city">Higashihiroshima</addr-line>, <country>Japan</country></aff></contrib-group><author-notes><corresp id="cor1">Dr Kohei Okuyama; <email xlink:href="KOkuyama@mdanderson.org">KOkuyama@mdanderson.org</email></corresp><fn fn-type="COI-statement" id="fn3"><p>No, there are no competing interests.</p></fn></author-notes><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>31</day><month>8</month><year>2025</year></pub-date><volume>13</volume><issue>8</issue><issue-id pub-id-type="pmc-issue-id">494366</issue-id><elocation-id>e012728</elocation-id><history><date date-type="received"><day>29</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>15</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>31</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="jitc-13-8.pdf"/><self-uri xlink:title="pdf" xlink:href="jitc-13-8.pdf"/><abstract><title>Abstract</title><p>The recent phase 3 trial of the Fc-silent anti-programmed cell death protein-1 (PD-1) antibody finotonlimab demonstrated promising clinical activity in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). However, an unexpected finding emerged: human papillomavirus (HPV)-positive patients&#8212;typically responsive to PD-1 blockade&#8212;did not appear to benefit, with a subgroup HR favoring the control arm. This clinical discrepancy raises important mechanistic questions. We hypothesize that the abrogation of Fc&#947; receptor (Fc&#947;R)-mediated functions, while designed to preserve PD-1<sup>+</sup> T cells, may inadvertently attenuate innate immune mechanisms that are especially relevant in virally driven tumors. In immune-inflamed HPV-positive HNSCC, antitumor activity may depend not only on T-cell activation but also on Fc&#947;R-dependent myeloid and natural killer cell function. These considerations prompt further evaluation of how Fc engineering may interact with tumor immune contexture, particularly in virally associated cancers. We suggest experimental validation and stratified analysis in future studies to clarify these context-specific effects.</p></abstract><kwd-group><kwd>Biomarker</kwd><kwd>Head and Neck Cancer</kwd><kwd>Immune Checkpoint Inhibitor</kwd><kwd>Viral-specific T cells</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><title>Commentary</title><p> The therapeutic landscape for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) has undergone a significant paradigm shift in recent years due to advancements in immunotherapy. The phase III trial (<ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT04146402">NCT04146402</ext-link>) investigating the combination of the anti-programmed cell death protein-1 (PD-1) antibody finotonlimab with platinum-based chemotherapy plus fluorouracil has garnered considerable attention, as this regimen demonstrated non-inferiority&#8212;and potentially superiority&#8212;compared with the conventional EXTREME regimen. This trial revealed notable clinical benefits in the finotonlimab combination arm, including prolonged median overall survival (OS) and improved objective response rate (ORR), thereby reinforcing the clinical value of incorporating immune checkpoint inhibitors (ICIs) from first-line therapy. Regarding safety, the incidence of severe immune-related adverse events remained within manageable limits, and no unexpected safety signals were reported.<xref rid="R1" ref-type="bibr"><sup>1</sup></xref></p><p>Nonetheless, several limitations of the study merit consideration. First, stratified analyses by histological subtypes and primary tumor sites were not sufficiently addressed. Given the known heterogeneity in treatment response among oral cavity, oropharyngeal, and laryngeal cancers, such analyses are critical. Second, subgroup analysis based on programmed death-ligand 1 expression, particularly using combined positive score, was limited. From the standpoint of personalized immunotherapy, this represents a missed opportunity for biological insight. Third, exploratory analyses investigating biomarkers associated with treatment resistance or response, and their correlation with the tumor immune microenvironment, remain in preliminary stages and warrant further investigation in future translational studies.</p><p>A particularly important issue pertains to human papillomavirus (HPV) status, especially in oropharyngeal cancers. Previous trials such as KEYNOTE-048 and CheckMate 141 demonstrated greater efficacy of PD-1 blockade in HPV<sup>+</sup> subgroups.<xref rid="R2" ref-type="bibr"><sup>2 3</sup></xref> Clinically, HPV<sup>+</sup> tumors tend to exhibit enhanced antitumor immune activity, often classified as &#8220;hot tumors&#8221;.<xref rid="R4" ref-type="bibr"><sup>4</sup></xref> While similar trends could be anticipated in this study, the small sample size of HPV<sup>+</sup> patients and the results of the forest plot analysis (figure 2 in the original paper<xref rid="R1" ref-type="bibr"><sup>1</sup></xref>), in which the HR for the HPV<sup>+</sup> subgroup exceeded 1.0 and favored the placebo arm, introduce a degree of uncertainty regarding the clinical efficacy of finotonlimab in this context.<xref rid="R1" ref-type="bibr"><sup>1</sup></xref> This finding should be interpreted cautiously, and further experimental and clinical studies are needed to clarify the therapeutic scope of finotonlimab for HPV-associated cancers.</p><p>Despite these limitations, the clinical significance of the <ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT04146402">NCT04146402</ext-link> trial remains substantial. Finotonlimab, a humanized IgG4 monoclonal antibody targeting PD-1, incorporates Fc engineering designed to abrogate Fc&#947; receptor (Fc&#947;R) binding, thereby minimizing antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.<xref rid="R5" ref-type="bibr"><sup>5</sup></xref> As far as their clinical trial results suggest, while this structural modification is intended to preserve PD-1<sup>+</sup> effector T cells and enhance antitumor immunity, its biological impact may differ in HPV<sup>+</sup> HNSCC. In HPV<sup>+</sup> tumors, immune activation and antigen presentation are critical determinants of therapeutic response. It is plausible that the complete abrogation of Fc-mediated effector functions by finotonlimab may impair tumor antigen release and subsequent cross-presentation by antigen-presenting cells, ultimately affecting the quality and magnitude of T-cell priming. Indeed, the study by Dahan <italic toggle="yes">et al</italic> provides direct evidence that the antitumor activity of PD-1&#8211;targeting antibodies is not solely determined by checkpoint blockade itself, but also by Fc-mediated interactions with Fc&#947;R-expressing effector cells, which enhance innate and adaptive immune responses.<xref rid="R6" ref-type="bibr"><sup>6</sup></xref> While anti-PD-1 antibodies are often engineered to reduce Fc&#947;R binding, complete abrogation may unintentionally silence beneficial innate immune circuits. Moreover, Fc&#947;R-expressing innate immune cells, including natural killer cells and M1-like macrophages, may play a more prominent role in the elimination of virally transformed cells in HPV<sup>+</sup> tumors. In a murine model, Da Silva <italic toggle="yes">et al</italic> demonstrated that the uptake of HPV16 virus-like particles by dendritic cells is significantly mediated by Fc&#947;RII and Fc&#947;RIII. Mice lacking these receptors showed impaired dendritic cell maturation and reduced priming of E7-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells following vaccination. These findings suggest that Fc&#947;R engagement may play a critical role in shaping adaptive immune responses against HPV-associated antigens, highlighting a potential immunological consequence of using Fc-silent antibodies in virally driven tumors.<xref rid="R7" ref-type="bibr"><sup>7</sup></xref> Furthermore, macrophages play a central role in the tumor microenvironment by contributing to tissue remodeling and clearance, eliminating transformed cells through phagocytosis,<xref rid="R8" ref-type="bibr"><sup>8</sup></xref> and regulating inflammation via cytokine production. Harnessing these functions, therapeutic strategies that target tumor-associated macrophages (TAMs) using ICIs with Fc effector activity are becoming increasingly plausible. This is based on the ability of TAMs to mediate antibody-dependent cellular phagocytosis through Fc&#947;Rs (<xref rid="F1" ref-type="fig">figure 1</xref>).<xref rid="R9" ref-type="bibr"><sup>9</sup></xref> While Fc-mediated effector functions are known to play a pivotal role in the efficacy of many therapeutic antibodies, their specific contribution to antitumor immunity in HPV-associated malignancies has not yet been fully elucidated. By eliminating these Fc-dependent effector pathways, finotonlimab may exhibit attenuated antitumor efficacy to HPV<sup>+</sup> tumors compared with other PD-1 inhibitors that retain partial Fc&#947;R engagement.</p><fig position="float" id="F1" fig-type="figure" orientation="portrait"><label>Figure 1</label><caption><title>Schematic model illustrating the hypothesized role of Fc-effector function in antitumor immunity against HPV<sup>+</sup> HNSCC. In Fc-active PD-1 blockade, Fc&#947;R-mediated interactions activate macrophages and NK cells, enhance antigen presentation, and promote T-cell priming. In contrast, Fc-silent PD-1 antibodies like finotonlimab lack this engagement, which may attenuate adaptive immune responses in HPV+HNSCCs. ADCC, antibody-dependent cellular cytotoxicity; ADCP, antibody-dependent cellular phagocytosis; APC, antigen-presenting cells; Fc&#947;R, Fc&#947; receptor; HNSCC, head and neck squamous cell carcinoma; HPV, human papillomavirus; NK, natural killer; PD-1, programmed cell death protein-1.</title></caption><graphic position="float" orientation="portrait" xlink:href="jitc-13-8-g001.jpg"/></fig><p>These observations warrant further investigation. Future studies should aim to compare the antiviral and antitumor immune responses elicited by Fc-competent versus Fc-silent PD-1 antibodies in preclinical HPV<sup>+</sup> models. In addition, comparative analyses of the tumor immune microenvironment&#8212;such as CD8<sup>+</sup>/CD4<sup>+</sup> T cell ratios and M1/M2 macrophage polarization&#8212;in HPV<sup>+</sup> versus HPV<sup>&#8722;</sup> settings may elucidate differential mechanisms of action and inform rational design of next-generation immunotherapies.</p><p>Regarding the &#8220;quality&#8221; of immune cells, recent updated evidence suggests that the mere presence of tumor-infiltrating T cells may not directly correlate with favorable treatment outcomes. For instance, the peripheral (rim area) localization of regulatory T cells rather than intratumoral accumulation,<xref rid="R10" ref-type="bibr"><sup>10</sup></xref> the presence of tissue-resident memory T cells,<xref rid="R11" ref-type="bibr"><sup>11</sup></xref> and the proximity of tertiary lymphoid structures to the tumor<xref rid="R12" ref-type="bibr"><sup>12</sup></xref> have emerged as potential predictive markers for ICI responsiveness. Integrating these emerging immunological parameters into the evaluation of finotonlimab may provide critical insight for the future of personalized immunotherapy. Therefore, future clinical trials should also address the optimization of treatment strategies involving finotonlimab, including combination with other chemotherapeutic agents or ICIs, neoadjuvant applications, and concurrent use with radiotherapy.</p><p>In consideration of the potential application of finotonlimab in the neoadjuvant setting, the phase I/II clinical trial CheckMate 358&#8212;which investigated the safety and efficacy of anti-PD-1 therapy in patients with resectable, high-risk HPV<sup>+</sup> and HPV<sup>&#8722;</sup> HNSCC&#8212;provides important context. This trial demonstrated that pathologic tumor regression was more frequent in HPV<sup>+</sup> tumors (23.5%) compared with HPV<sup>&#8722;</sup> tumors (5.9%) following neoadjuvant nivolumab administration, and that the treatment was generally well tolerated. Notably, the authors emphasized that radiographic assessment of ORR using RECIST criteria underestimated the extent of tumor regression observed histologically, suggesting the limitation of relying solely on imaging-based evaluation in the context of neoadjuvant ICI therapy.<xref rid="R13" ref-type="bibr"><sup>13</sup></xref></p><p>In this clinical trial evaluating finotonlimab in R/M-HNSCC, OS was reported as the primary endpoint.<xref rid="R1" ref-type="bibr"><sup>1</sup></xref> However, in the context of HPV<sup>+</sup> disease, it would be of particular importance to clarify how RECIST-based ORR evolved in HPV<sup>+</sup> versus HPV<sup>&#8722;</sup> subgroups, as such data could provide critical insights. A comparison of RECIST responses between these subgroups may help to assess the feasibility and potential effectiveness of finotonlimab in the neoadjuvant setting, particularly when interpreted in light of the findings from the nivolumab cohort in the CheckMate 358.</p><p>In conclusion, the <ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT04146402">NCT04146402</ext-link> trial not only substantiates the clinical efficacy of finotonlimab but also serves as a pivotal milestone toward more individualized immunotherapeutic approaches in HPV<sup>+</sup> HNSCC. Overcoming the limitations discussed above may further enhance treatment precision and achieve more durable clinical benefits.</p></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.</p></fn><fn fn-type="other"><p><bold>Patient consent for publication:</bold> Not applicable.</p></fn><fn fn-type="other"><p><bold>Ethics approval:</bold> Not applicable.</p></fn><fn fn-type="other"><p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p></fn><fn fn-type="other"><p><bold>Collaborators:</bold> N/A.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Guo</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><etal>et al</etal></person-group><article-title>Finotonlimab with chemotherapy in recurrent or metastatic head and neck cancer: a randomized phase 3 trial</article-title><source>Nat Med</source><year>2024</year><volume>30</volume><fpage>2568</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1038/s41591-024-03110-7</pub-id><pub-id pub-id-type="pmid">38942993</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferris</surname><given-names>RL</given-names></name><name name-style="western"><surname>Blumenschein</surname><given-names>G</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Fayette</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck</article-title><source>N Engl J Med</source><year>2016</year><volume>375</volume><fpage>1856</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1602252</pub-id><pub-id pub-id-type="pmid">27718784</pub-id><pub-id pub-id-type="pmcid">PMC5564292</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burtness</surname><given-names>B</given-names></name><name name-style="western"><surname>Harrington</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Greil</surname><given-names>R</given-names></name><etal>et al</etal></person-group><article-title>Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study</article-title><source>The Lancet</source><year>2019</year><volume>394</volume><fpage>1915</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(19)32591-7</pub-id><pub-id pub-id-type="pmid">31679945</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mandal</surname><given-names>R</given-names></name><name name-style="western"><surname>&#350;enbabao&#287;lu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Desrichard</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>The head and neck cancer immune landscape and its immunotherapeutic implications</article-title><source>JCI Insight</source><year>2016</year><volume>1</volume><elocation-id>e89829</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.89829</pub-id><pub-id pub-id-type="pmid">27777979</pub-id><pub-id pub-id-type="pmcid">PMC5070962</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Preclinical Characterization of Efficacy and Pharmacodynamic Properties of Finotonlimab, a Humanized Anti-PD-1 Monoclonal Antibody</article-title><source>Pharmaceuticals (Basel)</source><year>2025</year><volume>18</volume><elocation-id>395</elocation-id><pub-id pub-id-type="doi">10.3390/ph18030395</pub-id><pub-id pub-id-type="pmid">40143171</pub-id><pub-id pub-id-type="pmcid">PMC11946465</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dahan</surname><given-names>R</given-names></name><name name-style="western"><surname>Sega</surname><given-names>E</given-names></name><name name-style="western"><surname>Engelhardt</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Fc&#947;Rs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis</article-title><source>Cancer Cell</source><year>2015</year><volume>28</volume><fpage>285</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2015.08.004</pub-id><pub-id pub-id-type="pmid">26373277</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Da Silva</surname><given-names>DM</given-names></name><name name-style="western"><surname>Fausch</surname><given-names>SC</given-names></name><name name-style="western"><surname>Verbeek</surname><given-names>JS</given-names></name><etal>et al</etal></person-group><article-title>Uptake of human papillomavirus virus-like particles by dendritic cells is mediated by Fcgamma receptors and contributes to acquisition of T cell immunity</article-title><source>J Immunol</source><year>2007</year><volume>178</volume><fpage>7587</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.178.12.7587</pub-id><pub-id pub-id-type="pmid">17548594</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okuyama</surname><given-names>K</given-names></name><name name-style="western"><surname>Fukushima</surname><given-names>H</given-names></name><name name-style="western"><surname>Naruse</surname><given-names>T</given-names></name><etal>et al</etal></person-group><article-title>Cell-in-cell structure in cancer: evading strategies from anti-cancer therapies</article-title><source>Front Oncol</source><year>2023</year><volume>13</volume><elocation-id>1248097</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2023.1248097</pub-id><pub-id pub-id-type="pmid">37790755</pub-id><pub-id pub-id-type="pmcid">PMC10544585</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gorvel</surname><given-names>L</given-names></name><name name-style="western"><surname>Olive</surname><given-names>D</given-names></name></person-group><article-title>Tumor associated macrophage in HPV<sup>+</sup> tumors: Between immunosuppression and inflammation</article-title><source>Semin Immunol</source><year>2023</year><volume>65</volume><fpage>101671</fpage><pub-id pub-id-type="doi">10.1016/j.smim.2022.101671</pub-id><pub-id pub-id-type="pmid">36459926</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Redman</surname><given-names>JM</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>J</given-names></name><name name-style="western"><surname>Robbins</surname><given-names>Y</given-names></name><etal>et al</etal></person-group><article-title>Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-&#946; blockade in HPV-unrelated head and neck cancer</article-title><source>J Clin Invest</source><year>2022</year><volume>132</volume><elocation-id>e161400</elocation-id><pub-id pub-id-type="doi">10.1172/JCI161400</pub-id><pub-id pub-id-type="pmid">35727629</pub-id><pub-id pub-id-type="pmcid">PMC9479764</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luoma</surname><given-names>AM</given-names></name><name name-style="western"><surname>Suo</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><etal>et al</etal></person-group><article-title>Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy</article-title><source>Cell</source><year>2022</year><volume>185</volume><fpage>2918</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2022.06.018</pub-id><pub-id pub-id-type="pmid">35803260</pub-id><pub-id pub-id-type="pmcid">PMC9508682</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sadeghirad</surname><given-names>H</given-names></name><name name-style="western"><surname>Monkman</surname><given-names>J</given-names></name><name name-style="western"><surname>Tan</surname><given-names>CW</given-names></name><etal>et al</etal></person-group><article-title>Spatial dynamics of tertiary lymphoid aggregates in head and neck cancer: insights into immunotherapy response</article-title><source>J Transl Med</source><year>2024</year><volume>22</volume><elocation-id>677</elocation-id><pub-id pub-id-type="doi">10.1186/s12967-024-05409-y</pub-id><pub-id pub-id-type="pmid">39049036</pub-id><pub-id pub-id-type="pmcid">PMC11267849</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferris</surname><given-names>RL</given-names></name><name name-style="western"><surname>Spanos</surname><given-names>WC</given-names></name><name name-style="western"><surname>Leidner</surname><given-names>R</given-names></name><etal>et al</etal></person-group><article-title>Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial</article-title><source>J Immunother Cancer</source><year>2021</year><volume>9</volume><elocation-id>e002568</elocation-id><pub-id pub-id-type="doi">10.1136/jitc-2021-002568</pub-id><pub-id pub-id-type="pmid">34083421</pub-id><pub-id pub-id-type="pmcid">PMC8183204</pub-id></element-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>